Holly E. Barker

Parkville, VIC 3052, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 45 publications

High-throughput drug screening identifies EGFR/MAPK pathway targeting sensitivities in organoid models of ovarian carcinosarcoma.

High-throughput drug screening identifies EGFR/MAPK pathway targeting sensitivities in organoid models of ovarian carcinosarcoma.

Journal: Journal of experimental & clinical cancer research : CR

Published: September 10, 2025

Genomics of ovarian cancers and the potential of precision medicine.

Genomics of ovarian cancers and the potential of precision medicine.

Journal: Therapeutic advances in medical oncology

Published: February 19, 2025

Farletuzumab ecteribulin and MORAb-109, folate receptor alpha and mesothelin targeting antibody-drug conjugates, show activity in poor prognosis gynaecological cancer models.

Farletuzumab ecteribulin and MORAb-109, folate receptor alpha and mesothelin targeting antibody-drug conjugates, show activity in poor prognosis gynaecological cancer models.

Journal: Clinical and translational medicine

Published: November 27, 2024

Genomics of cervical, vulvar and vaginal cancers and the potential of precision medicine.

Genomics of cervical, vulvar and vaginal cancers and the potential of precision medicine.

Journal: Therapeutic advances in medical oncology

Published: November 03, 2024

Genomics of uterine malignancies and the potential of precision medicine.

Genomics of uterine malignancies and the potential of precision medicine.

Journal: Therapeutic advances in medical oncology

Published: November 03, 2024

BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance.

BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance.

Journal: Molecular cancer

Published: May 23, 2024

A Matched Molecular and Clinical Analysis of the Epithelioid Haemangioendothelioma Cohort in the Stafford Fox Rare Cancer Program and Contextual Literature Review.

A Matched Molecular and Clinical Analysis of the Epithelioid Haemangioendothelioma Cohort in the Stafford Fox Rare Cancer Program and Contextual Literature Review.

Journal: Cancers

Published: July 27, 2023

The microtubule inhibitor eribulin demonstrates efficacy in platinum-resistant and refractory high-grade serous ovarian cancer patient-derived xenograft models.

The microtubule inhibitor eribulin demonstrates efficacy in platinum-resistant and refractory high-grade serous ovarian cancer patient-derived xenograft models.

Journal: Therapeutic advances in medical oncology

Published: July 01, 2023

A risk-reward examination of sample multiplexing reagents for single cell RNA-Seq.

A risk-reward examination of sample multiplexing reagents for single cell RNA-Seq.

Journal: Genomics

Published: June 25, 2023

CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and CCNE1 amplified ovarian cancer.

CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and CCNE1 amplified ovarian cancer.

Journal: iScience

Published: May 17, 2023

Signatures of exposure to childhood trauma in young adults in the structure and neurochemistry of the superior temporal gyrus.

Signatures of exposure to childhood trauma in young adults in the structure and neurochemistry of the superior temporal gyrus.

Journal: Journal of psychopharmacology (Oxford, England)

Published: April 18, 2023

BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance.

BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance.

Journal: medRxiv : the preprint server for health sciences

Published: March 30, 2023

Showing 1-12 of 45

Last Updated: 09/26/2026